

Special Issue

Current Management of Early and Advanced Rectal Cancer

Message from the Guest Editor

In 2020, multimodal management of rectal cancer is still a matter of debate. From the surgical point of view, anterior rectal resection has been the standard of care for a long time. However, in the era of personalized medicine, surgical approaches should also be tailored. Early rectal cancer might be treated by open or minimally invasive local excision, but its feasibility and oncologic safety after neoadjuvant chemoradiation are still controversial. At the same time, locally recurrent or stage IV rectal cancers require a multimodal approach, which is still not completely standardized nor feasible outside tertiary referral centers. Induction chemotherapy, re-chemoradiation, hadrontherapy, totally neoadjuvant treatment, organ-saving strategies, radiomics, indocyanine green-guided surgery, beyond-TME resections, and extending indications for sphincter-saving surgery are not widely performed, but could potentially optimize the treatment strategy. The aim of this Special Issue is to provide an up-to-date milieu of papers focused on the evolving multimodal therapy for rectal cancer.

Guest Editor

Dr. Filiberto Belli

Colorectal Surgery Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy

Deadline for manuscript submissions

closed (15 November 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/62300

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)